Lufotrelvir

Lufotrelvir

Legal status
Legal status	US: Investigational drug
Identifiers
IUPAC name [(3S)-3-[(2S)-2-[(4-methoxy-1H-indol-2-yl)formamido]-4-methylpentanamido]-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butoxy]phosphonic acid
CAS Number	2468015-78-1
PubChem CID	154699467
DrugBank	DB16514
UNII	XJ51YOB1SC
KEGG	D12172
ChEBI	CHEBI:173073
Chemical and physical data
Formula	C24H33N4O9P
Molar mass	552.521 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC
InChI InChI=1S/C24H33N4O9P/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26H,7-10,12H2,1-3H3,(H,25,30)(H,27,31)(H,28,32)(H2,33,34,35)/t14-,17-,18-/m0/s1 Key:FQKALOFOWPDTED-WBAXXEDZSA-N

Lufotrelvir (PF-07304814) is an antiviral drug developed by Pfizer which acts as a 3CL protease inhibitor. It is a prodrug with the phosphate group being cleaved in vivo to yield the active agent PF-00835231. Lufotrelvir is in human clinical trials for the treatment of COVID-19, and shows good activity against COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion, and so has been the less favoured candidate for clinical development overall.

See also

• 3CLpro-1
• Bemnifosbuvir
• Baloxavir marboxil
• Favipiravir
• GC376
• GRL-0617
• Molnupiravir
• Remdesivir
• Ribavirin
• Rupintrivir
• S-217622
• Triazavirin